Navigation Links
Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Date:7/24/2012

vir against all major HIV subtypes resistant to current therapies, which may allow activity against tenofovir-resistant viruses (e.g., K65R), and against HBV.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile. 

About Chimerix
Led by an experienced antiviral drug development team, Chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

Chimerix's lead compound, CMX001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded DNA (dsDNA) viruses including cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus and variola (smallpox).  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (HSCT) recipients.  To date, more than 750 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Antiviral activity from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity that are associated with currently available therapies, indicate that CMX001 has the potential to improve outcomes for stem cell and solid organ transplant recipients.  Chimerix has completed an End of Phase 2 meeting with the FDA for CMX001 and is
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
6. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
7. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
8. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
9. Bacterin International Signs Its Third National GPO Contract with Novation
10. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
11. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... AMSTERDAM , July 25, 2014 ... America is returning for the seventh year to São ... to 7 th August 2014. The event will co-locate ... America,s most comprehensive meeting point for the pharmaceutical ... the top 25 countries for pharmaceutical sales are now exploring ...
(Date:7/25/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... second quarter 2014 financial results before the NASDAQ Global ... same day, Arena will host a conference call and ... Time). The conference call may be ... for international callers. Please specify to the operator that ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... Perrigo Company today announced that it will attend the ... Asthma & Immunology Conference (ACAAI) Nov. 3-8 at the ... Boston. The ACAAI is a professional ... the medical subspecialty of allergy and immunology.  It is ...
... The oncology market continues to be a rapid ... aspects of successfully launching a new oncology product is ... Strategic Marketing function. The regulatory environment, ... marketplace present significant challenges for Global Strategic Marketing (GSM) ...
Cached Medicine Technology:Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology 2Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology 3Global Strategic Marketing Key to Success in Oncology Launches in the Pharmaceutical Sector 2
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Sport Court® provided and ... Nike National Invitational Tournament (NIT) in Chicago at ... National Tournament (USJN) in Washington D.C. at the ... these prestigious national tournaments included 44 Sport Court Maple ... playing surface at McCormick Place for the NIT, and ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 The ... Family Fun Fest on Sunday, July 27 at Discovery ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, The ... in The Heights. , “We’re thrilled to be ... year,” said Heather Belcher who owns the Sugarland-Missouri City ...
Breaking Medicine News(10 mins):Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2
... Several years ago, scientists at Beth Israel Deaconess Medical ... regarding the Akt molecular pathway, a popular target for ... protein Akt1 was actively preventing cancer cells ... was actually promoting breast cancer cell migration. And, ...
... be one of the leading causes of oral cancer, ... experimental animals has traditionally been limited to examining the ... rather than on observing the effects of carcinogens that ... completed study conducted collaboratively by Dr. Joseph Guttenplan, a ...
... for building new organs to replace damaged livers, blood vessels ... cells grown in a lab dish to form 3-D shapes ... of Health Sciences and Technology (HST) have come up with ... cells in cubes and arranging them into 3-D structures, just ...
... strong, healthy bones. But new research from North Carolina ... the earliest days of life could have a more ... obesity than previously thought. During an 18-day trial ... levels of bone density and strength in 12 piglets ...
... physical competition, not attraction, was central in winning ... State anthropologist., "There is sexual competition in many ... professor of biological anthropology. Many researchers have ... sexual selection. They thought that people,s mating success ...
... ... (NWS), a leading provider of water conservation and water management services, was recently awarded ... ... 2010 -- National Water Services, Inc. (NWS), a leading provider of ...
Cached Medicine News:Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link 2Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Calcium in early life may prevent obesity later 2Health News:It was brawn over beauty in human mating competition 2Health News:National Water Services, Inc. Receives WBE Certification 2
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... Single Use Biofragmentable Anastomosis Rings., ... and side-to-side anastomosis., ,VALTRAC™ Ring ... intestinal anastomoses but not for gastric ... be used in any disease process ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Medicine Products: